Case 1: A 64-Year-Old Hispanic Woman with Estrogen-Receptor-Positive Breast Cancer

Program Description:

This case focuses on a 64-year-old Hispanic female with type 2 diabetes mellitus who is diagnosed with estrogen-receptor- (ER) and progesterone-receptor- (PR) positive breast cancer. This patient is notable not only because breast cancer is the leading cause of cancer death among Hispanic women, but that patients with preexisting diabetes who develop cancer have an approximately 50% higher risk for long-term, all-cause mortality. Using the National Comprehensive Cancer Network guidelines as a point of departure for treatment, the clinical decisions for this patient centered on the type and duration of endocrine therapy in the adjuvant setting, the role in particular of tamoxifen and aromatase inhibitor therapy, and the management of associated adverse events.

INTENDED AUDIENCE:

Oncologists, thoracic surgeons, pathologists, internists, ob/gyns, and other clinicians who treat or manage women with breast cancer.

Activity Objectives:

After taking part in this educational activity, participants should be better able to:

• Evaluate the efficacy of aromatase inhibition for adjuvant therapy in patients with estrogen-receptor-positive breast cancer


• Manage the adverse events that arise from the use of aromatase inhibitors

Faculty:

William J. Gradishar, M.D., FACP
Betsy Bramsen Professor of Breast Oncology
Professor of Medicine
Director, Maggie Daley Center for Women's Cancer Care
Robert H. Lurie Comprehensive Cancer Center
Northwestern University Feinberg School of Medicine
Northwestern Memorial Hospital
Chicago, IL

Disclosures:

To resolve identified conflicts of interest, the educational content was fully reviewed by Hemedicus Inc. The resulting certified activity was found to provide educational content that is current, evidence-based, and commercially balanced.

Faculty Disclosures
As an ACCME-accredited provider of continuing medical education, Hemedicus Inc., requires that faculty participating in a CME activity disclose any relevant financial relationship they may have with a pharmaceutical or medical-equipment company, product, or service within the preceding 12 months, including any relationship with the commercial supporter of this activity. The faculty reported the following:

Dr. Gradishar has no real or apparent conflicts of interest to report.

Review Committee Disclosure
In accordance with the Accreditation Council for Continuing Medical Education (ACCME), Hemedicus, Inc., requires that any person who is in a position to control the content of a CME activity must disclose all relevant financial relationships they have with a commercial interest. Accordingly the staff of Hemedicus Inc., as planners and reviewers, disclose as follows:

Hemedicus Inc.
Jonathan Wood: No relevant financial relationships with any commercial interest.
Robin Simak: No relevant financial relationships with any commercial interest.
Erilyn Riley: No relevant financial relationships with any commercial interest.

Haymarket Medical Education
Lynne Callea: No relevant financial relationships with any commercial interest.
Nick Zittell: No relevant financial relationships with any commercial interest.
Debra Hughes: No relevant financial relationships with any commercial interest.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in this educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Furthermore, participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.

Disclaimer
The content and views presented in this educational activity are those of the presenters and do not necessarily reflect those of Hemedicus Inc., or the supporter. This material is prepared based upon a review of multiple sources of information, but it is not exhaustive of the subject matter. Therefore, healthcare professionals and other individuals should review and consider other publications and materials on the subject matter before relying solely upon the information contained within this educational activity.

Privacy Policy
To view the Hemedicus Inc., privacy policy, please click here.

To view the myCME privacy policy, please click here.

Accredited Provider:

This activity is accredited by Hemedicus, Inc.



Produced by

Commercial Supporter:

There is no commercial support for this educational activity.

Instructions:

To obtain credit, a score of 70% or better is required. This CME is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the posttest survey, and have received your digital copy of your credit certificate. Your online certificate will be saved on myCME.com within your Profile/Exam History, which you can then access at any time.

If you have any questions relating to your certificate or technical issues with this activity, please contact myCME.Support@haymarketmedical.com.

If you have any questions relating to the accreditation of this activity, please contact Robin Simak, Managing Director, CME Compliance, Hemedicus Inc., rsimak@hemedicus.com.

SYSTEM REQUIREMENTS:

WINDOWS PC SYSTEM REQUIREMENTS:
266-MHz Pentium II; Windows 98 or higher; 64 MB RAM; 800 x 600 screen resolution set for “High Color (16-Bit)”; Macromedia Flash Player 6 or higher.

MACINTOSH^® SYSTEM REQUIREMENTS:
Power Mac g3 at 300 MHz; System 8.5 or higher (excluding Mac OSX); 96 MB RAM; 20 MB minimum hard disk space available; 800 x 600 screen resolution set to “Thousands of Colors”; Macromedia Flash Player 6 or higher.